Regeneron Pharmaceuticals (REGN)

• Market cap: $77.4B
• 1 day: 6.17%
• 5 days: 12.16%
• 1 month: 18.41%
• 3 months: 4.42%
• 6 months: -0.42%
• Year to date: -4.89%
• 1 year: 33.13%
• 5 years: 28.49%
• 10 years: 70.12%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Employees: 15,410